Friday, August 21, 2026
GlobeNewsInfo Logo
Home / Business & Corporate / EIB backs Théa with EUR 150 million loan to expand European eye care R&D and manufacturing

EIB backs Théa with EUR 150 million loan to expand European eye care R&D and manufacturing

Published on
EIB backs Théa with EUR 150 million loan to expand European eye care R&D and manufacturing
Image used for illustrative purposes only. GlobeNewsInfo / Visuals

The European Investment Bank (EIB) has approved a EUR 150 million financing facility for French ophthalmology firm Théa, backed by InvestEU. The funds will support research into retinal, rare inherited, glaucoma, and dry eye conditions while expanding European industrial capacity, reinforcing regional pharmaceutical supply resilience and high-skill employment.

FRANCE; ITALY —The European Investment Bank (EIB) has extended a EUR 150 million loan to Théa to advance ophthalmic research and development and scale industrial operations across Europe, building on a EUR 50 million credit facility provided in 2021. Supported by the InvestEU guarantee framework, the transaction targets new active molecules, drug formulations, and delivery mechanisms across retinal disorders, rare inherited ocular diseases, glaucoma, and dry eye.

Founded in 1994 and headquartered in Clermont-Ferrand, France, Théa is a family-owned pharmaceutical group focused exclusively on ophthalmology, operating in more than 75 countries through 35 subsidiaries with roughly 2,500 employees. The group generated EUR 1,020 million in turnover in 2025 and directs over 12% of annual revenue toward research and innovation.

This financing matters because aging populations and chronic ocular conditions are increasing clinical demand for specialized therapies, while supply chain resilience in pharmaceuticals has become a core policy priority in Europe. Pairing laboratory R&D with domestic manufacturing infrastructure-such as Théa's industrial site in Milan-helps retain specialized scientific talent, shorten development-to-production cycles, and reduce reliance on external supply chains.

Across the pharmaceutical and biotechnology sectors, the deal underscores continued public-private risk sharing under InvestEU to de-risk long-horizon clinical development and specialized manufacturing upgrades required to meet evolving European regulatory standards. Healthcare providers, patients with underserved eye conditions, and European industrial suppliers stand to benefit as novel delivery systems and therapies progress toward commercialization.

For corporate strategists and institutional investors, the facility signals sustained institutional appetite for vertically integrated European life sciences leaders that combine consistent R&D reinvestment with regional production assets. Companies competing in ophthalmology and specialty pharma may face heightened benchmarks around supply security and localized manufacturing scale, while investors can view EU-backed debt instruments as a key mechanism financing capital-intensive European healthcare expansion.

About GlobeNewsInfo

GlobeNewsInfo is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.

More on Business & Corporate

Latest Business News

Share this Article

Just In
1 hour ago NIB commits EUR 70 million ten-year facility to Nefco for Ukrainian municipal green projects 1 hour ago EIB backs Théa with EUR 150 million loan to expand European eye care R&D and manufacturing 1 hour ago UAE Ministry of Finance launches bids for penetration testing and security vulnerability assessment project 1 hour ago Eimskip expands Reyðarfjörður cargo capacity with electric mobile harbor crane